Insomnia Therapeutics Market to grow by USD 1 billion from 2022-2027 | North America to account for 60% of market growth – Technavio

NEW YORK, Nov. 27, 2023 /PRNewswire/ — The insomnia therapeutics market size is expected to grow by USD 1 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 5.49% during the forecast period, according to Technavio Research. The market is categorized based on Type (Drug and Devices), Distribution Channel (Prescription and OTC), and Geography (North America, Asia, Europe, and Rest of the World (ROW)). North America will contribute 60% to the growth of the global market during the forecast period. The high prevalence of insomnia and the growing awareness of its negative effects of insomnia on the health and well-being of people who suffer from it drive the growth of the regional insomnia therapeutics market. A significant availability of various forms of prescription drugs, over-the-counter (OTC) drugs, and non-drug treatments can be witnessed in the region. Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Merck and Co., Inc., Sanofi S.A., and Purdue Pharma L.P are some of the major players in the market. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a Free PDF Sample Report

Company Profile:

Abbott Laboratories, Astellas Pharma Inc., Aurobindo Pharma Ltd., Eisai Co. Ltd., Electromedical Products International Inc., Idorsia Pharmaceuticals Ltd., INNOVATIVE NEUROLOGICAL DEVICES LLC, Mallinckrodt Plc, MEDICE Arzneimittel Putter GmbH and Co. KG, Merck and Co. Inc., Minerva Neurosciences Inc., Neurim Pharmaceuticals Ltd., Pfizer Inc., Questex LLC, Sanofi, Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Vanda Pharmaceuticals Inc., Viatris Inc.

Astellas Pharma Inc: The company offers insomnia therapeutics namely Myslee tablets.

To gain access to more vendor profiles available with Technavio, buy the report!

Insomnia Therapeutics Market: Segmentation Analysis

The drug segment is significant during the forecast period. The pharmaceutical drugs in this segment can be classified into various classes, including sedative-hypnotics, benzodiazepines, non-benzodiazepines, melatonin receptor agonists, orexin receptor antagonists, and other medications. 

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report

“Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021”- Technavio

Insomnia Therapeutics Market: Driver & Trend:

Driver

Increasing prevalence of insomniaTechnological advancements in diagnostics and treatmentRising healthcare expenditure and insurance coverage

There is a growing prevalence of insomnia across the globe. Alterations in the way of life, including disturbed sleep habits, greater use of electronics before going to sleep, and high levels of stress are some of the results of this prevalence. Medical problems, psychological illnesses, and specific drugs are some of the influencing factors.

The increased focus on non-pharmacological treatments is an emerging market trend. Identify key trends, drivers, and challenges in the market. Download a sample report to gain access to this information.

Related Reports:

The Alzheimer’s disease therapeutics market is estimated to grow at a CAGR of 8.91% between 2022 and 2027. The size of the market is forecast to increase by USD 4,391.9 million.

The global neuromuscular disease therapeutics market size is estimated to grow by USD 6,513.28 million at a CAGR of 10.3% between 2022 and 2027.

What are the key data covered in this insomnia therapeutics market report?

CAGR of the market during the forecast periodDetailed information on factors that will drive the growth of the insomnia therapeutics market between 2022 and 2027.Precise estimation of the insomnia therapeutics market size and its contribution to the market in focus on the parent marketAccurate predictions about upcoming trends and changes in consumer behaviorGrowth of the insomnia therapeutics market across North America, Europe, Asia, and ROWA thorough analysis of the market’s competitive landscape and detailed information about vendorsComprehensive analysis of factors that will challenge the growth of insomnia therapeutics market vendors.

ToC:

Executive Summary

Market Landscape

Market Sizing

Historic Market Sizes

Five Forces Analysis

Market Segmentation by Type

Market Segmentation by Distribution Channel

Market Segmentation by Geography

Customer Landscape

Geographic Landscape

Drivers, Challenges, & Trends

Company Landscape

Company Analysis

Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/insomnia-therapeutics-market-to-grow-by-usd-1-billion-from-2022-2027–north-america-to-account-for-60-of-market-growth—technavio-301997337.html

SOURCE Technavio